A new study has revealed that a new drug can provide hope to thousands of sufferers of the skin condition psoriasis.
Trials of a new drug found 40 per cent of participants showed complete clearance of their plaques, while 90 per cent experienced some improvement.
The study, conducted at the University of Manchester, tested the effectiveness of the drug ixekizumab.
Half the participants were given the new drug, ixekizumab while the other half were given a placebo, or a widely used drug for psoriasis called etanercept.
The ixekizumab groups showed quick and extensive improvements in their condition, outperforming the groups on placebo or etanercept.
Around half of these patients showed improvement as early as week four of the trial and up to 71 per cent had shown a high level of improvement in their symptoms.
Psoriasis - characterised by an abundance of skin cells - causes raised bumps known as "plaques" to grow on the skin. These can be flaky, scaly and itchy for sufferers.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
